Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis (Q28484646)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis	scientific article

Statements

scholarly article

0 references

1 reference

based on heuristic

inferred from title

Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis (English)

0 references

hyperparathyroidism

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

secondary hyperparathyroidism

1 reference

based on heuristic

inferred from title

author name string

Qian Zhang

1

0 references

Ming Li

2

0 references

Li You

3

0 references

Haiming Li

4

0 references

Li Ni

5

0 references

Yong Gu

6

0 references

Chuanming Hao

7

0 references

Jing Chen

8

0 references

language of work or name

0 references

publication date

2012

0 references

0 references

7

0 references

10

0 references

e48070

0 references

copyright license

Creative Commons Attribution 4.0 International

25 October 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

19 March 2017

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

19 March 2017

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

19 March 2017

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

19 March 2017

Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

19 March 2017

Quantitative Synthesis in Systematic Reviews

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

7 April 2017

Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

7 April 2017

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

29 September 2017

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

29 September 2017

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

29 September 2017

The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

29 September 2017

Meta-analysis of biochemical and patient-level effects of calcimimetic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

29 September 2017

Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCl

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

29 September 2017

The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

29 September 2017

Extracellular calcium sensing and extracellular calcium signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

29 September 2017

The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

29 September 2017

Calcium handling by the mammalian kidney.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

29 September 2017

Renal osteodystrophy: pathogenesis and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

29 September 2017

Economic Analysis of Cinacalcet in Combination With Low-Dose Vitamin D Versus Flexible-Dose Vitamin D in Treating Secondary Hyperparathyroidism in Hemodialysis Patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

2 June 2018

Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

2 June 2018

Biochemical markers of bone turnover in the diagnosis of renal osteodystrophy: what do we have, what do we need?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

2 June 2018

The hyperparathyroidism of chronic renal failure: A disorder of growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

2 June 2018

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0048070

21 January 2018

Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0048070

21 January 2018

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0048070

21 January 2018

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0048070

21 January 2018

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0048070

21 January 2018

Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0048070

21 January 2018

First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0048070

21 January 2018

An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

27 November 2018

Vascular calcification in the uremic patient: a cardiovascular risk?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485048

27 November 2018

Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23133549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet

1 reference

https://pubmed.ncbi.nlm.nih.gov/23133549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23133549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23133549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism

1 reference

https://pubmed.ncbi.nlm.nih.gov/23133549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Actions of 1 alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on mineral metabolism in man. I. Effects on net absorption of phosphorus

1 reference

https://pubmed.ncbi.nlm.nih.gov/23133549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23133549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NPS R-568 halts or reverses osteitis fibrosa in uremic rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/23133549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism

1 reference

https://pubmed.ncbi.nlm.nih.gov/23133549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0048070

0 references

2012PLoSO...748070Z

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28484646&oldid=1962803522"